Home › Oncolytics Biotech's REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer
 

Keywords :   


Oncolytics Biotech's REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

2015-02-17 15:06:44| Biotech - Topix.net

Oncolytics Biotech Inc. , a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. "This is the second indication for which we have received Orphan Drug Designation in the United States," said Dr. Brad Thompson, President and CEO of Oncolytics.

Tags: treatment drug cancer receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
07.11Tropical Depression Fourteen-E Forecast Discussion Number 5
More »